MedTrace Logo

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

NCT07593209 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-05-18

No results posted yet for this study

Summary

Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.

Conditions

  • Malignant Tumor

Interventions

DEVICE

68Ga- DOTA-EphA2 PET/CT Imaging of Malignant Tumor

Study of the Radioligand 68Ga- DOTA-EphA2 for PET/CT Imaging of Malignant Tumor

Sponsors & Collaborators

  • First Hospital of China Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07593209 on ClinicalTrials.gov